靶向HER3依赖的核AKT激活可改善非小细胞肺癌的放射治疗
该体外与小鼠移植瘤模型研究探讨非小细胞肺癌中AKT1的亚细胞分布及HER家族受体对核AKT磷酸化与放射应答的作用。结果显示电离辐射诱导的核AKT磷酸化主要依赖HER3表达及表皮生长因子受体酪氨酸激酶激活;HER3中和抗体帕曲妥单抗联合放疗改善了移植瘤模型的肿瘤生长延迟。
要点
- 电离辐射诱导的核AKT磷酸化主要依赖HER3表达及EGFR酪氨酸激酶激活。
- HER3中和抗体帕曲妥单抗及HER3-siRNA在体外减弱DNA双链断裂修复。
- 帕曲妥单抗联合放疗改善移植瘤模型的放疗所致肿瘤生长延迟效果。
核心结论
- 电离辐射诱导的核AKT激活发生在核内,在非小细胞肺癌中主要依赖HER3表达。
- 作者认为靶向HER3联合放疗可能为选定非小细胞肺癌患者提供合乎逻辑的治疗选择以供研究。
研究设计与样本
- 采用遗传学方法和药理学抑制剂在体外研究非小细胞肺癌细胞中AKT1的亚细胞分布及HER家族受体成员对核AKT激活的作用。
- 应用ɤH2AX焦点实验研究AKT激活信号通路对DNA双链断裂修复的作用。
- 使用小鼠肿瘤移植瘤模型在体内研究所发现的激活核AKT的信号通路对肿瘤放射应答的影响。
主要发现
- 数据提示电离辐射及HER家族受体配体刺激均未诱导内源性AKT1快速核转位。
- GFP标记的外源性AKT1在未照射条件下转位至核,电离辐射未刺激该转位。
- AKT抑制剂MK2206使GFP-AKT1在胞质组分中蓄积,提示其核转位受损。
- 电离辐射诱导的核AKT磷酸化主要依赖HER3表达及表皮生长因子受体酪氨酸激酶激活。
- HER3中和抗体帕曲妥单抗及HER3-siRNA在体外减弱DNA双链断裂修复;帕曲妥单抗联合放疗改善移植瘤模型的肿瘤生长延迟效果。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: AKT1 must be present and activated in the nucleus immediately after irradiation to stimulate AKT1-dependent double-strand breaks (DSB) repair through the fast non-homologous end-joining (NHEJ) repair process. We investigated the subcellular distribution of AKT1 and the role of HER family receptor members on the phosphorylation of nuclear AKT and radiation response. MATERIALS AND METHODS: Using genetic approaches and pharmacological inhibitors, we investigated the subcellular distribution of AKT1 and the role of HER family receptor members on the activation of nuclear AKT in non-small cell lung cancer (NSCLC) cells in vitro. ɤH2AX foci assay was applied to investigate the role of AKT activating signaling pathway on DSB repair. A mouse tumor xenograft model was used to study the impact of discovered signaling pathway activating nuclear AKT on the radiation response of tumors in vivo. RESULTS: Our data suggests that neither ionizing radiation (IR) nor stimulation with HER family receptor ligands induced rapid nuclear translocation of endogenous AKT1. GFP-tagged exogenous AKT1 translocated to the nucleus under un-irradiated conditions and IR did not stimulate this translocation. Nuclear translocation of GFP-AKT1 was impaired by the AKT inhibitor MK2206 as shown by its accumulation in the cytoplasmic fraction. IR-induced phosphorylation of nuclear AKT was primarily dependent on HER3 expression and tyrosine kinase activation of epidermal growth factor receptor. In line with the role of AKT1 in DSB repair, the HER3 neutralizing antibody patritumab as well as HER3-siRNA diminished DSB repair in vitro. Combination of patritumab with radiotherapy improved the effect of radiotherapy on tumor growth delay in a xenograft model. CONCLUSION: IR-induced activation of nuclear AKT occurs inside the nucleus that is mainly dependent on HER3 expression in NSCLC. These findings suggest that targeting HER3 in combination with radiotherapy may provide a logical treatment option for investigation in selected NSCLC patients.
引用
- Toulany M, Iida M, Lettau K, et al. Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer. Radiother Oncol. 2022. PMID: 35839938. doi:10.1016/j.radonc.2022.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。